The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea ... index (BMI) and apnea-hypopnea index (AHI) values ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

The first medication for obstructive sleep apnea has been approved by ... and clinically meaningful reduction in events of apnea or hypopnea," and a large share of participants achieved remission ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...